Followers | 229 |
Posts | 14669 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
![](https://investorshub.advfn.com/uicon/467032.png?cb=1478627184)
Monday, June 01, 2015 9:34:41 PM
This is for Bristol Myers Squibb's combined trial for untreated melanoma for Ipilimumab and Nivolumab.
Here's the journal article...
http://www.nejm.org/doi/full/10.1056/NEJMoa1504030#t=articleTop
Here's how the Russian Times presented it...
‘Huge paradigm shift’: Biggest cancer breakthrough in 40 years sees tumors disappear (yes, we'd like a header like that too)
http://rt.com/news/263881-cancer-treatment-breakthrough-cure/
This article in the Russian Times is written very positively, while the Time Magazine article below is not quite as glowing in it's report...
Time
http://time.com/3902868/cancer-tumors-melanoma-ipilimumab-nivolumab/
(too bad Time didn't mention what the two combined cancer drugs are. They did, however, say in the subhead this...
However, the associated side-effects of the dual treatment are amplified
And here's is the closing rise in percentages for both BMY and NWBO...
Today's percentage of rise in price for BMY... 2.89%
Today's percentage of rise in price for NWBO... 1.90%
So not bad... I'll bet BMY had hoped for a bigger jump as well.
I just don't think the market gets it yet. I'm not sure they know what to make of immunotherapy. They hear it's the paradigm shifter in cancer... but the big news they hear too are the nasty side effects... which of course, don't happen with DCVax. :)
We gots to do some educating here.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM